BACKGROUND: Despite high curability, some testicular cancer (TC) patient groups may have increased mortality. We provide a detailed age- and histology-specific comparison of population-based relative survival of TC patients in Europe and the USA. Design Using data from 12 European cancer registries and the USA Surveillance, Epidemiology and End Results 9 database, we report survival trends for patients diagnosed with testicular seminomas and nonseminomas between 1993-1997 and 2003-2007. Additionally, a model-based analysis was used to compare survival trends and relative excess risk (RER) of death between Europe and the USA adjusting for differences in age and histology. RESULTS: In 2003-2007, the 5-year relative survival of patients with testicular seminoma was at least 98% among those aged <50 years, survival of patients with nonseminoma remained 3%-6% units lower. Despite improvements in the relative survival of nonseminoma patients aged ≥ 50 years by 13%-18% units, survival remained markedly lower than the survival of seminoma patients of the same age. Model-based analyses showed increased RERs for nonseminomas, older, and European patients. CONCLUSIONS: There remains little room for survival improvement among testicular seminoma patients, especially for those aged <50 years. Older TC patients remain at increased risk of death, which seems mainly attributable to the lower survival among the nonseminoma patients.
BACKGROUND: Despite high curability, some testicular cancer (TC) patient groups may have increased mortality. We provide a detailed age- and histology-specific comparison of population-based relative survival of TC patients in Europe and the USA. Design Using data from 12 European cancer registries and the USA Surveillance, Epidemiology and End Results 9 database, we report survival trends for patients diagnosed with testicular seminomas and nonseminomas between 1993-1997 and 2003-2007. Additionally, a model-based analysis was used to compare survival trends and relative excess risk (RER) of death between Europe and the USA adjusting for differences in age and histology. RESULTS: In 2003-2007, the 5-year relative survival of patients with testicular seminoma was at least 98% among those aged <50 years, survival of patients with nonseminoma remained 3%-6% units lower. Despite improvements in the relative survival of nonseminoma patients aged ≥ 50 years by 13%-18% units, survival remained markedly lower than the survival of seminomapatients of the same age. Model-based analyses showed increased RERs for nonseminomas, older, and European patients. CONCLUSIONS: There remains little room for survival improvement among testicular seminomapatients, especially for those aged <50 years. Older TC patients remain at increased risk of death, which seems mainly attributable to the lower survival among the nonseminoma patients.
Authors: C J Sullivan; K P Murphy; P D McLaughlin; M Twomey; K N O'Regan; D G Power; M M Maher; O J O'Connor Journal: Eur Radiol Date: 2014-12-13 Impact factor: 5.315
Authors: Alexander M Busch; Fabrizio Galimberti; Kristen E Nehls; Monic Roengvoraphoj; David Sekula; Bin Li; Yongli Guo; James Direnzo; Steven N Fiering; Michael J Spinella; David J Robbins; Vincent A Memoli; Sarah J Freemantle; Ethan Dmitrovsky Journal: Cancer Biol Ther Date: 2014-02-04 Impact factor: 4.742
Authors: Klaus-Peter Dieckmann; Hanna Richter-Simonsen; Magdalena Kulejewski; Raphael Ikogho; Henrik Zecha; Petra Anheuser; Uwe Pichlmeier; Hendrik Isbarn Journal: Urol Int Date: 2018-04-12 Impact factor: 2.089
Authors: V Matulevicius; B Zilaitiene; R T Preiksa; I Banisauskaite; J Jurevičiūtė; S Abramavicius; I Matuleviciute; T Kurakovas; R Ostrauskas; R Verkauskiene; V Urbanavicius Journal: Acta Endocrinol (Buchar) Date: 2016 Apr-Jun Impact factor: 0.877